An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. Issue 4 (21st March 2019)

• Record Type: Journal Article
• Authors: Sobas, Marta; Montesinos, Pau; Boluda, Blanca; Bernal, Teresa; Vellenga, Edo; Nomdedeu, Josep; González-Campos, Jose; Chillón, Maria; Holowiecka, Aleksandra; Esteve, Jordi; Bergua, Juan; González-Sanmiguel, José David; Gil-Cortes, Cristina; Tormo, Mar; Salamero, Olga; Manso, Felix; Fernández, Isolda; de la Serna, Javier; Moreno, María-José; Pérez-Encinas, Manuel; Krsnik, Isabel; Ribera, Josep-Maria; Escoda, Lourdes; Lowenberg, Bob; Sanz, Miguel Angel
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 4(2019)
• Page Start: 1030
• Page End: 1035
• Publication Date: 2019-03-21
• Subjects: Acute promyelocytic leukemia -- CD56 -- ATRA -- chemotherapy -- prognostic -- relapse; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1516875
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = .02) and 5-years cumulative incidence of relapse (33% versus 10%, p = .006), irrespectively of the Sanz score (low-risk 47% versus 5%, p < .001; intermediate 23% versus 7%, p < .001; and high-risk 42% versus 21%, p = .007). In the multivariate analysis, CD56 + ( p < .0001), higher relapse-risk score ( p = .001), and male gender ( p = .05) retained the independent predictive value. CD56+ APL also showed a greater risk of CNS relapse (6% versus 1%, p < .001) and lower 5-year OS (75% versus 83%, p = .003). The AIDA-based LPA2012 trial, with an intensified consolidation schedule for CD56+ APL, will elucidate whether an intensified consolidation schedule could mitigate the relapse rate in this setting.